MétaCan
Menu
← Back to cohort

CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.

2015· article· en· W2182385064 on OpenAlexaff
Massimo Federico, Monica Bellei, Stefano Luminari, Steven M. Horwitz, Silvia Montoto, Emanuele Zucca, Stefano Pileri, Young Hyeh Ko, Pier Luigi Zinzani, Joseph M. Connors, Francine M. Foss, Aaron Polliack, María Elena Cabrera, Won Seog Kim, Michele Spina, Cármino Antônio De Souza, Sabela Bobillo Varela, Iván Dlouhy, Ranjana H. Advani, Julie M. Vose

Bibliographic record

VenueJournal of Clinical Oncology · 2015
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsCD30MedicineAnaplastic large-cell lymphomaCHOPInternal medicinePathologyBrentuximab vedotinBiopsyProspective cohort studyOncologyLymphoma

Abstract

fetched live from OpenAlex

8552 Background: CD30 is a member of TNF-alpha receptor family that might have important therapeutic implications with the advent of targeted therapies. Several PTCLs subtypes have been reported in literature to be associated to variable CD30 expression. We investigated the frequency of CD30 expression among PTCLs subtypes registered in the T-Cell Project and correlated it with clinical features and outcome. Methods: The T-cell Project is a prospective, international study in patients (pts) with newly diagnosed aggressive PTCLs. Clinical, laboratory and disease localization data at diagnosis as well as therapy details and follow-up information are collected at a dedicated website via secure HTTP protocols. Central review of diagnostic biopsy is planned. Results: From Sept 2006 to Jan 2015, 1308 pts were registered in the T-Cell Project by 73 sites from 14 countries world-wide. As from the 792 pathology forms filled out by site local staff CD30 expression was tested in 490 pts (62%) and reported as CD30+ in 349 (71%) and CD30- in 141 (29%). Frequency of CD30 expression in different subtypes is shown in the Table. CD30+ pts tended to be younger (54 vs 58 yrs, P = .03) with less extranodal involvement (65% vs 78%, P = .01) than CD30-. CHOP like regimens were the most common irrespective of CD30 status (63% in both groups, P = 1.0). In the group of pts with any histology but ALCL, no difference in CR rate (44% vs 51%, P = .26), 5-yr PFS (29% vs 22%, P = .57) and OS (44% vs 29%, P = .17) was observed between CD30+ and CD30- pts. Brentuximab use in first line was noted in only 5 pts enrolled in clinical trials. Conclusions: Data from the T-cell project confirm that CD30 is expressed in many PTCLs other than ALCL, thus suggesting a routine assessment for all PTCLs. Again, this analysis suggests that CD30 expression has no prognostic significance. The very limited use of anti CD30 targeted therapy in this sample doesn’t allow to establish the predictive value of CD30 expression in PTCLs. CD30- N, % CD30+ N, % PTCL,NOS 85, 41 120, 59 AITL 16, 42 50, 76 ALCL 0, 0 145, 100 NKTCL 13, 48 14, 52 EATL 11, 46 13, 54 Other 16, 70 7, 30

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0020.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.123
GPT teacher head0.442
Teacher spread0.318 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicLymphoma Diagnosis and Treatment→French-language works237,207→